Daiichinkyo Co (FRA:D4S) Other Gross PPE : €2,590 Mil (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Other Gross PPE?

Daiichinkyo Co's Other Gross PPE for the quarter that ended in Mar. 2024 was €2,590 Mil.

Daiichinkyo Co's quarterly Other Gross PPE increased from Sep. 2023 (€2,425 Mil) to Dec. 2023 (€2,514 Mil) and increased from Dec. 2023 (€2,514 Mil) to Mar. 2024 (€2,590 Mil).

Daiichinkyo Co's annual Other Gross PPE increased from Mar. 2022 (€2,328 Mil) to Mar. 2023 (€2,438 Mil) and increased from Mar. 2023 (€2,438 Mil) to Mar. 2024 (€2,590 Mil).

Daiichinkyo Co Other Gross PPE Historical Data

The historical data trend for Daiichinkyo Co's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Other Gross PPE Chart

Daiichinkyo Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Other Gross PPE

Get a 7-Day Free Trial

2,076.61

2,050.03

2,328.40

2,438.08

2,589.51

Daiichinkyo Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															2,438.08	2,443.03	2,425.15	2,514.08	2,589.51

Daiichinkyo Co Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Daiichinkyo Co (FRA:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (FRA:D4S) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (FRA:D4S) Headlines

No Headlines